*UNIQURE ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION GRANTED TO AMT-130 FOR THE TREATMENT OF HUNTINGTON’S DISEASE
*UNIQURE NV: ADDITIONAL REGULATORY UPDATE & GUIDANCE ON BIOLOGICS LICENSE APPLICATION SUBMISSION EXPECTED IN Q2 2025
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 17-APR-202511:17:00.057 GMT